Overview

Pediatric Rare Genetic Causes of Obesity

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this phase 3 clinical trial is to evaluate the safety and tolerability of setmelanotide in pediatric patients aged 2 to <6 years with obesity due to either (1) biallelic variants of the POMC, PCSK1 or LEPR genes or (2) Bardet-Biedl Syndrome (BBS).
Phase:
Phase 3
Details
Lead Sponsor:
Rhythm Pharmaceuticals, Inc.